Patents by Inventor Woo Sun Kwon

Woo Sun Kwon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTCAL COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING STREPTONIGRIN AND RAPAMYCIN AS ACTIVE INGREDIENTS
    Publication number: 20200237738
    Abstract: Disclosed is a pharmaceutical composition for preventing or treating cancer, containing streptonigrin and an mTOR inhibitor as active ingredients; and a composition for inhibiting angiogenesis, containing streptonigrin and a vascular endothelial growth factor (VEGF) inhibitor as active ingredients. Also disclosed is a cancer treatment method using streptonigrin and an mTOR inhibitor, a use in the preparation of anticancer drugs and a composition to be used in cancer prevention or treatment; and a method for inhibiting angiogenesis by using streptonigrin and a VEGF inhibitor, a use in the preparation of drugs for inhibiting angiogenesis and a composition to be used in angiogenesis inhibition. When a renal cancer cell line is treated with streptonigrin, which is a TGase2 inhibitor, in combination with rapamycin, which is an mTOR inhibitor, a cancer cell death effect can be exhibited to be greater than that when cancer cells are treated with each thereof, individually.
    Type: Application
    Filed: September 21, 2018
    Publication date: July 30, 2020
    Applicant: MD BIOLAB CO., LTD.
    Inventors: Soo Youl KIM, Sun Young RHA, Seung Hoon BEOM, Nam Hoon CHO, Woo Sun KWON
  • MARKER FOR PREDICTING TREATMENT RESPONSE TO ANTI-CANCER AGENT IN SOLID CANCER PATIENTS
    Publication number: 20190100806
    Abstract: The present invention relates to a marker for predicting a responsiveness of a solid cancer patient to an anticancer agent. The marker according to the present invention can be advantageously used to select a subgroup, who effectively responds to an anticancer therapy with a specific anticancer agent, from among solid cancer patients, or to determine a therapy method for treatment of solid cancer patients.
    Type: Application
    Filed: March 23, 2016
    Publication date: April 4, 2019
    Inventors: Jaeyoung KIM, Jingmin CHE, Hyun Cheol CHUNG, Sun Young RHA, Woo Sun KWON, Tae Soo KIM
  • Combination therapy using c-Met inhibitor and IGF-1R inhibitor for c-Met inhibitor resistant cancers
    Patent number: 10064939
    Abstract: A method of preventing and/or treating a cancer, the method including co-administering a dual inhibitor of c-Met (hereinafter, ‘c-Met inhibitor’) and an IGF-1R inhibitor to a subject in need thereof and a use of IGF-1R as a marker for resistance to a c-Met inhibitor.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: September 4, 2018
    Assignees: SAMSUNG ELECTRONICS CO., LTD., YONSEI UNIVERSITY, UNIVERSITY-INDUSTRY FOUNDATION (UIF)
    Inventors: Seon Hui Shim, Ji Min Lee, Soo Yeon Jung, Woo Sun Kwon, Kyung Ah Kim, Jeong Min Kim, Sun Young Rha, Won Suk Lee
  • COMBINATION THERAPY USING C-MET INHIBITOR AND IGF-1R INHIBITOR
    Publication number: 20160144027
    Abstract: A method of preventing and/or treating a cancer, the method including co-administering a dual inhibitor of c-Met (hereinafter, ‘c-Met inhibitor’) and an IGF-1R inhibitor to a subject in need thereof and a use of IGF-1R as a marker for resistance to a c-Met inhibitor.
    Type: Application
    Filed: November 23, 2015
    Publication date: May 26, 2016
    Inventors: Seon Hui Shim, Ji Min Lee, Soo Yeon Jung, Woo Sun Kwon, Kyung Ah Kim, Jeong Min Kim, Sun Young Rha, Won Suk Lee